Substituted tetracycline compounds

Inventors

Kim, Oak • Assefa, Haregewein • Honeyman, Laura

Assignees

Paratek Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8318706-B2

Patent

Publication Date

2012-11-27

Expiration Date


Abstract

The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.

Core Innovation

The disclosed subject matter provides substituted tetracycline compounds represented by Formula I through Formula XVI, encompassing minocycline and sancycline derivatives, or pharmaceutically acceptable salts thereof. Synthetic transformations yield diverse 7-, 9-, and 10-substituted derivatives bearing substituents such as aminoalkyl, heteroaryl, oxime, and alkoxycarbonyl groups. Pharmaceutical compositions comprising the substituted compounds and a pharmaceutically acceptable carrier are also provided, although the specific technical problem being solved is not explicitly described in patent.

The disclosure details compound characterizations alongside antibacterial, cytotoxicity, phototoxicity, oxidation-stability, and in vivo biological evaluations. Several substituted tetracycline derivatives demonstrate antibacterial efficacy and provide 100% survival in infection models, while compound B displays an enhanced oxidation half-life over minocycline. In addition, compounds A and P reduce carrageenan-induced paw edema with efficacy comparable to or exceeding standard tetracyclines in tetracycline-responsive states.

Claims Coverage

The provided claims identify two independent claims directed to substituted tetracycline compounds, comprising two inventive features.

Substituted tetracycline compound of formula I

A compound of formula I in which X is CR6′R6 or C=CR6′R6; E is NR7dR7e or OR7f; R2, R2′, R4′, R4a, and R4b are independently hydrogen or alkyl; R3, R10, R11, and R12 are hydrogen; R4 is NR4aR4b; R5 and R5′ are independently hydroxyl, hydrogen, or alkyl; R6 and R6′ are independently hydrogen, hydroxyl, or alkyl; R7a, R7b, R7c, R7d, R7e, and R7f are independently hydrogen, alkyl, alkenyl, aryl, or arylalkyl, or specified groups are linked to form a ring; R8 is hydrogen; and R9 is hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, amino, or aminoalkyl; or a pharmaceutically acceptable salt thereof.

Compound of depicted structure

A compound of the structure depicted in the claim, or a pharmaceutically acceptable salt thereof.

The independent claims cover substituted tetracycline compounds defined by formula I and a separately depicted chemical structure, or pharmaceutically acceptable salts thereof.

Stated Advantages

Many of the compounds showed antibacterial activity across the tested organisms.

Compound B had a reported oxidation half-life of 495 seconds, compared with 8.2 seconds for minocycline.

Several compounds provided 100% survival in a mouse S. aureus infection model at tested doses.

Compounds A and P reduced carrageenan-induced rat paw edema, with activity comparable to or better than doxycycline or minocycline.

Documented Applications

Treatment of a bacterial, viral, or parasitic infection in a subject by administering an effective amount of the claimed compound.

A pharmaceutical composition for treating malaria.

Treatment of tetracycline-responsive states, including bacterial infections, inflammation, and neoplasms.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.